On the other hand, osimertinib has also been reported to have an ORR of 50% and mDoR of 9.8 months for treating EGFR mutation‐positive NSCLC patients with major uncommon EGFR mutations.6 Here, EGFR is linked to non-small cell lung carcinoma.